Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal
Abstract Context The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective We characterized the population with LAP and recurrence-free survival (RFS). Methods This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumor...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 106; no. 9; pp. 2726 - 2737 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
US
Oxford University Press
01.09.2021
Endocrine Society |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-972X 1945-7197 1945-7197 |
| DOI | 10.1210/clinem/dgab202 |
Cover
| Abstract | Abstract
Context
The behavior of locally advanced pheochromocytoma (LAP) remains unknown.
Objective
We characterized the population with LAP and recurrence-free survival (RFS).
Methods
This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence.
Results
Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis.
Conclusion
LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification. |
|---|---|
| AbstractList | Context The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective We characterized the population with LAP and recurrence-free survival (RFS). Methods This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence. Results Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis. Conclusion LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification. Abstract Context The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective We characterized the population with LAP and recurrence-free survival (RFS). Methods This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence. Results Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis. Conclusion LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification. Abstract Context The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective We characterized the population with LAP and recurrence-free survival (RFS). Methods This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence. Results Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis. Conclusion LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification. Locally advanced pheochromocytoma (LAP) behavior remains unknown. To characterize this population and its recurrence-free survival (RFS). A retrospective multicentric study run within the ENDOCAN-COMETE network and GTE from 2003 to 2018. 11 French Referral centers. Patients with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. Recurrence was defined as the reappearance of the tumor, including local site and/or distant metastasis. The primary endpoint was RFS analysis. The secondary endpoints were characterization, overall survival (OS) and prognostic factors of recurrence. Among 950 patients, 90 exhibited LAP criteria (9%). 55 met the inclusion criteria (median age: 53 years-old, 61% males, 14% with a germline mutation, 84% with a catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes and 22 (40%) vascular invasions. After a median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of a metastatic disease. Median RFS was 115 months (range, 6-168). The recurrences were local in 2 patients, distant in 2 and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5cm (p=0.019) and Ki-67>2% (p=0.028) were identified as independent significant prognostic factors in multivariate analysis. LAP represents 9% of pheochromocytoma's population and is characterized by a metastatic behavior. This study paved the way of a future pathological TNM classification. The behavior of locally advanced pheochromocytoma (LAP) remains unknown.CONTEXTThe behavior of locally advanced pheochromocytoma (LAP) remains unknown.We characterized the population with LAP and recurrence-free survival (RFS).OBJECTIVEWe characterized the population with LAP and recurrence-free survival (RFS).This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence.METHODSThis retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence.Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis.RESULTSAmong 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis.LAP represents 9% of pheochromocytoma's population and has a metastatic behavior. This study paves the way for future pathological TNM classification.CONCLUSIONLAP represents 9% of pheochromocytoma's population and has a metastatic behavior. This study paves the way for future pathological TNM classification. Context: The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective: We characterized the population with LAP and recurrence-free survival (RFS). Methods: This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence. Results: Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis. Conclusion: LAP represents 9% of pheochromocytoma's population and has a metastatic behavior. This study paves the way for future pathological TNM classification. Key Words: locally advanced pheochromocytoma, metastatic pheochromocytoma, prognostic factor, recurrence-free survival |
| Audience | Academic |
| Author | Borson-Chazot, Françoise Jannin, Arnaud Lamartina, Livia Pierre, Peggy Libé, Rosella Laboureau, Sandrine Al Ghuzlan, Abir Hescot, Ségolène Amar, Laurence Hadoux, Julien Lussey-Lepoutre, Charlotte Castinetti, Frédéric Renaudin, Karine Vezzosi, Delphine Laroche, Suzanne Drui, Delphine Baudin, Eric Gimenez-Roqueplo, Anne-Paule Leboulleux, Sophie DoCao, Christine Raffin Sanson, Marie-Laure Moog, Sophie Batisse Ligner, Marie Faron, Matthieu Guerin, Carole Deniziaut, Gabrielle |
| Author_xml | – sequence: 1 givenname: Sophie surname: Moog fullname: Moog, Sophie organization: Endocrine Oncology Unit, Gustave Roussy, F-94805, Villejuif, France – sequence: 2 givenname: Frédéric orcidid: 0000-0002-1808-8800 surname: Castinetti fullname: Castinetti, Frédéric organization: Aix Marseille Université, INSERM, U1251, Department of Endocrinology, Marseille Medical Genetics (MMG), centre de référence des maladies rares de l’hypophyse (HYPO), hôpital de la Conception, France, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France – sequence: 3 givenname: Christine surname: DoCao fullname: DoCao, Christine organization: Department of Endocrinology, CHU Lille, 59000 Lille, France – sequence: 4 givenname: Laurence orcidid: 0000-0003-3942-4276 surname: Amar fullname: Amar, Laurence organization: Department of hypertension, AP-HP, Hôpital Européen Georges Pompidou, 75015 Paris, France – sequence: 5 givenname: Julien surname: Hadoux fullname: Hadoux, Julien organization: Endocrine Oncology Unit, Gustave Roussy, F-94805, Villejuif, France – sequence: 6 givenname: Charlotte orcidid: 0000-0003-2228-0106 surname: Lussey-Lepoutre fullname: Lussey-Lepoutre, Charlotte organization: Université de Paris, INSERM, PARCC, Equipe labellisée contre le cancer, F-75015 Paris, France – sequence: 7 givenname: Françoise orcidid: 0000-0003-2515-7840 surname: Borson-Chazot fullname: Borson-Chazot, Françoise organization: Fédération d’endocrinologie, Hôpital Louis Pradel, Hospices Civils de Lyon, EA 7425, Université Lyon1, 69500 Lyon, France – sequence: 8 givenname: Delphine surname: Vezzosi fullname: Vezzosi, Delphine organization: Department of Endocrinology, CHU Toulouse, 40031 Toulouse, France – sequence: 9 givenname: Delphine surname: Drui fullname: Drui, Delphine organization: Department of Endocrinology, L’institut du thorax, 44200 CHU Nantes, France – sequence: 10 givenname: Sandrine surname: Laboureau fullname: Laboureau, Sandrine organization: Department of Endocrinology, CHU Angers, 49933 Angers, France – sequence: 11 givenname: Marie-Laure surname: Raffin Sanson fullname: Raffin Sanson, Marie-Laure organization: Department of Endocrinology&Nutrition, AP-HP, Hôpital Ambroise Paré, 92100 Boulogne-Billancourt, France – sequence: 12 givenname: Livia surname: Lamartina fullname: Lamartina, Livia organization: Endocrine Oncology Unit, Gustave Roussy, F-94805, Villejuif, France – sequence: 13 givenname: Peggy surname: Pierre fullname: Pierre, Peggy organization: Department of Endocrinology, CHU Tours, 37044 Tours, France – sequence: 14 givenname: Marie surname: Batisse Ligner fullname: Batisse Ligner, Marie organization: Department of Endocrinology, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France – sequence: 15 givenname: Ségolène surname: Hescot fullname: Hescot, Ségolène organization: Médecine Nucléaire, Institut Curie, 35 rue Dailly, 92210 Saint Cloud, France – sequence: 16 givenname: Abir surname: Al Ghuzlan fullname: Al Ghuzlan, Abir organization: Department of Anatomopathology, Gustave Roussy, 94805 Villejuif, France – sequence: 17 givenname: Karine surname: Renaudin fullname: Renaudin, Karine organization: Department of Anatomopathology, CHU de Nantes, 44200 Nantes, France – sequence: 18 givenname: Rosella surname: Libé fullname: Libé, Rosella organization: Department of Endocrinology, AP-HP, Hôpital Cochin, 75014 Paris, France – sequence: 19 givenname: Suzanne surname: Laroche fullname: Laroche, Suzanne organization: Department of Endocrinology, AP-HP, Hôpital La Pitié Salpêtrière, 75013 Paris, France – sequence: 20 givenname: Gabrielle surname: Deniziaut fullname: Deniziaut, Gabrielle organization: Department of Anatomopathology, AP-HP, Hôpital La Pitié-Salpêtrière, 75013 Paris, France – sequence: 21 givenname: Anne-Paule surname: Gimenez-Roqueplo fullname: Gimenez-Roqueplo, Anne-Paule organization: Université de Paris, INSERM, PARCC, Equipe labellisée contre le cancer, F-75015 Paris, France – sequence: 22 givenname: Arnaud surname: Jannin fullname: Jannin, Arnaud organization: Department of Endocrinology, CHU Lille, 59000 Lille, France – sequence: 23 givenname: Sophie surname: Leboulleux fullname: Leboulleux, Sophie organization: Endocrine Oncology Unit, Gustave Roussy, F-94805, Villejuif, France – sequence: 24 givenname: Carole surname: Guerin fullname: Guerin, Carole organization: Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Department of Endocrine Surgery, La Conception Hospital, 13005 Marseille, France – sequence: 25 givenname: Matthieu surname: Faron fullname: Faron, Matthieu organization: Department of biostatistics and epidemiology and INSERM U1018 CESP équipe ONCOSTAT, Institut Gustave Roussy, 94805 Villejuif, France – sequence: 26 givenname: Eric orcidid: 0000-0002-2198-3582 surname: Baudin fullname: Baudin, Eric email: eric.baudin@gustaveroussy.fr organization: Endocrine Oncology Unit, Gustave Roussy, F-94805, Villejuif, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33782697$$D View this record in MEDLINE/PubMed https://amu.hal.science/hal-03662818$$DView record in HAL |
| BookMark | eNqFktuL1DAUxoOsuLOrrz5KwRd96G4ubZL6VhbHFQYUL-hbOE3TnSxpU5N2YP57U2ZcdfFCCIHD7zvfOTnnDJ0MfjAIPSX4glCCL7Wzg-kv2xtoKKYP0IpURZkLUokTtMKYkrwS9OspOovxFmNSFCV7hE4ZE5LySqzQlw9GzyGYQZt8HYzJPs5hZ3fgsnoAt482ZnbINl6Dc_usbneQyDZ7vzVeb4Pvvd5PvodX2dqGOGX1OAawEdxj9LADF82T43uOPq9ff7q6zjfv3ry9qje5LiSfcqCFhkLostG4oW1HGgBBOikFkI6lYkXbAlAsDE536bGThusqRUtjqoqdo5eHvFtwagy2h7BXHqy6rjdqiWHGOZVE7khiXxzYMfhvs4mT6m3UxjkYjJ-joiUWpOCMyYQ-v4fe-jmkH4mKEZFq4YTxf1G0KhOCq_KXXDfgjLJD56cAerFWNZeSl0TwpZGLP1DptKa3Og29syn-m-DZ0XxuetPeNf9jtj8z6uBjDKa7QwhWy_Kow_Ko4_IkQXFPoO0Ek_VDKsW6v8uOI_Dz-D-L7-_U1tA |
| CitedBy_id | crossref_primary_10_1016_j_bulcan_2023_06_002 crossref_primary_10_3389_fendo_2021_762548 crossref_primary_10_7759_cureus_57643 crossref_primary_10_1007_s12020_023_03489_2 crossref_primary_10_3389_fendo_2024_1419028 crossref_primary_10_3390_cancers15112890 crossref_primary_10_3390_cancers15184666 crossref_primary_10_1210_clinem_dgab366 crossref_primary_10_3389_fendo_2024_1346052 crossref_primary_10_1016_j_mce_2024_112344 crossref_primary_10_1210_clinem_dgac677 |
| Cites_doi | 10.1530/ERC-19-0024 10.1002/(SICI)1096-9896(200006)191:2<175::AID-PATH615>3.0.CO;2-Z 10.1530/ERC-13-0494 10.1530/EJE-16-0189 10.1016/j.surg.2004.05.058 10.1210/jc.2010-1946 10.1007/978-3-319-40618-3 10.1016/j.surg.2016.05.050 10.1016/j.juro.2010.12.050 10.1136/jmedgenet-2018-105714 10.1210/jc.2017-00992 10.1371/journal.pone.0187398 10.1530/EJE-18-0608 10.1530/EJE-16-0033 10.1677/ERC-07-0074 10.1210/jc.2014-1498 10.1097/PAS.0b013e318190d12e 10.1038/nrendo.2016.185 10.1097/00000478-200205000-00002 10.1373/clinchem.2004.045484 10.1210/jc.2007-0709 10.1016/j.ccell.2017.01.001 10.1097/HJH.0000000000002438 10.1530/EJE-14-0113 10.1210/jc.2008-2697 10.4111/kju.2011.52.4.241 10.21037/tlcr.2017.09.04 10.1038/s41379-018-0110-y 10.1016/j.prp.2010.01.007 10.1016/j.surg.2019.04.030 10.1186/1471-2407-14-523 10.1038/ncomms7044 10.1210/jc.2018-01968 10.1016/j.surg.2008.02.007 10.1097/01.MP.0000056982.07160.E3 10.4158/EP15725.OR |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. COPYRIGHT 2021 Oxford University Press The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021 – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. – notice: COPYRIGHT 2021 Oxford University Press – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION NPM 7QP 7T5 7TM H94 K9. 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC |
| DOI | 10.1210/clinem/dgab202 |
| DatabaseName | CrossRef PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts ProQuest One Academic Middle East (New) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) PubMed AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | 2737 |
| ExternalDocumentID | oai_HAL_hal_03662818v1 A688651769 33782697 10_1210_clinem_dgab202 10.1210/clinem/dgab202 |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GroupedDBID | --- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 3O- 3V. 4.4 48X 53G 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABZA AACZT AAIMJ AAJQQ AAKAS AAPGJ AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYJJ ABBLC ABDFA ABDPE ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABUWG ABVGC ABWST ABXVV ACFRR ACGFO ACGFS ACPRK ACUTJ ACYHN ACZBC ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK ADZCM AELWJ AEMDU AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFQV AFFZL AFGWE AFKRA AFOFC AFRAH AFXAL AFYAG AGINJ AGKRT AGMDO AGQXC AGUTN AHMBA AHMMS AI. AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT APJGH AQDSO AQKUS ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CCPQU CDBKE CS3 D-I DAKXR DIK E3Z EBS EIHJH EJD EMOBN ENERS F5P FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC GX1 H13 HMCUK HVGLF HZ~ H~9 IAO IHR INH ITC J5H KBUDW KOP KQ8 KSI KSN L7B M1P M5~ MBLQV MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PQQKQ PROAC PSQYO REU ROX ROZ TEORI TJX TLC TMA TR2 TWZ UKHRP VH1 VVN W8F WHG WOQ X52 X7M YBU YFH YHG YOC YSK ZGI ZXP ZY1 ~02 ~H1 AAYXX ABXZS ADNBA AEMQT AEOTA AGORE AHGBF AJBYB ALXQX CITATION NU- PHGZM PHGZT NPM PMFND 7QP 7T5 7TM AEHZK H94 K9. PJZUB PPXIY PUEGO 7XB 8FK PKEHL PQEST PQUKI PRINS 7X8 1XC |
| ID | FETCH-LOGICAL-c486t-a24ca47c5bc0b2df1baa71f887a1f34537ddaa207e007eab20f8e6c9dda5ee993 |
| IEDL.DBID | BENPR |
| ISSN | 0021-972X 1945-7197 |
| IngestDate | Fri Sep 12 12:35:57 EDT 2025 Thu Sep 04 14:59:50 EDT 2025 Fri Sep 19 20:56:28 EDT 2025 Fri Sep 19 20:53:50 EDT 2025 Tue Jun 17 21:39:10 EDT 2025 Tue Jun 10 20:47:04 EDT 2025 Wed Feb 19 02:28:30 EST 2025 Tue Jul 01 01:11:01 EDT 2025 Thu Apr 24 23:11:34 EDT 2025 Fri Feb 07 10:35:42 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | metastatic pheochromocytoma locally advanced pheochromocytoma prognostic factor recurrence-free survival Locally advanced pheochromocytoma |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c486t-a24ca47c5bc0b2df1baa71f887a1f34537ddaa207e007eab20f8e6c9dda5ee993 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2198-3582 0000-0003-2515-7840 0000-0003-2228-0106 0000-0002-1808-8800 0000-0003-3942-4276 0000-0002-4816-670X 0000-0002-4824-8502 0000-0002-4247-3039 |
| PMID | 33782697 |
| PQID | 3170076136 |
| PQPubID | 2046206 |
| PageCount | 12 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03662818v1 proquest_miscellaneous_2507146338 proquest_journals_3170076136 proquest_journals_2956130958 gale_infotracmisc_A688651769 gale_infotracacademiconefile_A688651769 pubmed_primary_33782697 crossref_primary_10_1210_clinem_dgab202 crossref_citationtrail_10_1210_clinem_dgab202 oup_primary_10_1210_clinem_dgab202 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-09-01 |
| PublicationDateYYYYMMDD | 2021-09-01 |
| PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2021 |
| Publisher | Oxford University Press Endocrine Society |
| Publisher_xml | – name: Oxford University Press – name: Endocrine Society |
| References | Nagura (2021120108545005900_CIT0036) 1999; 12 Assadipour (2021120108545005900_CIT0009) 2017; 161 Turkova (2021120108545005900_CIT0018) 2016; 22 DeLellis (2021120108545005900_CIT0011) 2004 Kimura (2021120108545005900_CIT0014) 2014; 21 Chrisoulidou (2021120108545005900_CIT0019) 2007; 14 Tavangar (2021120108545005900_CIT0034) 2010; 206 Lenders (2021120108545005900_CIT0001) 2020; 38 Toledo (2021120108545005900_CIT0024) 2017; 13 Plouin (2021120108545005900_CIT0027) 2016; 174 Rindi (2021120108545005900_CIT0028) 2018; 31 Schovanek (2021120108545005900_CIT0032) 2014; 14 Lloyd (2021120108545005900_CIT0012) 2017 Stenman (2021120108545005900_CIT0026) 2019; 166 Pelosi (2021120108545005900_CIT0033) 2017; 6 Thompson (2021120108545005900_CIT0013) 2002; 26 Amar (2021120108545005900_CIT0005) 2007; 92 Crona (2021120108545005900_CIT0003) 2019; 26 Lenders (2021120108545005900_CIT0023) 2014; 99 Ben Aim (2021120108545005900_CIT0002) 2019; 56 Amin (2021120108545005900_CIT0022) 2017 van der Harst (2021120108545005900_CIT0007) 2000; 191 Feng (2021120108545005900_CIT0029) 2011; 185 Castro-Vega (2021120108545005900_CIT0039) 2015; 6 Baudin (2021120108545005900_CIT0010) 2014; 171 Fishbein (2021120108545005900_CIT0038) 2017; 31 Elder (2021120108545005900_CIT0037) 2003; 16 Ayala-Ramirez (2021120108545005900_CIT0008) 2011; 96 Koh (2021120108545005900_CIT0015) 2017; 12 Nomura (2021120108545005900_CIT0020) 2009; 94 Wu (2021120108545005900_CIT0040) 2009; 33 Eisenhofer (2021120108545005900_CIT0004) 2012; 48 Hamidi (2021120108545005900_CIT0017) 2017; 102 Hescot (2021120108545005900_CIT0016) 2019; 104 Amar (2021120108545005900_CIT0006) 2016; 175 Park (2021120108545005900_CIT0030) 2011; 52 Shen (2021120108545005900_CIT0031) 2004; 136 Strong (2021120108545005900_CIT0035) 2008; 143 Fassnacht (2021120108545005900_CIT0021) 2018; 179 Eisenhofer (2021120108545005900_CIT0025) 2005; 51 |
| References_xml | – volume: 26 start-page: 539 issue: 5 year: 2019 ident: 2021120108545005900_CIT0003 article-title: Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-19-0024 – volume: 191 start-page: 175 issue: 2 year: 2000 ident: 2021120108545005900_CIT0007 article-title: Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? publication-title: J Pathol. doi: 10.1002/(SICI)1096-9896(200006)191:2<175::AID-PATH615>3.0.CO;2-Z – volume: 21 start-page: 405 issue: 3 year: 2014 ident: 2021120108545005900_CIT0014 article-title: Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-13-0494 – volume: 175 start-page: R135 issue: 4 year: 2016 ident: 2021120108545005900_CIT0006 article-title: MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis publication-title: Eur J Endocrinol. doi: 10.1530/EJE-16-0189 – volume-title: WHO Classification of Tumours of Endocrine Organs year: 2017 ident: 2021120108545005900_CIT0012 – volume: 136 start-page: 1129 issue: 6 year: 2004 ident: 2021120108545005900_CIT0031 article-title: Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas publication-title: Surgery. doi: 10.1016/j.surg.2004.05.058 – volume: 96 start-page: 717 issue: 3 year: 2011 ident: 2021120108545005900_CIT0008 article-title: Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2010-1946 – start-page: 919 volume-title: AJCC Cancer Staging Manual year: 2017 ident: 2021120108545005900_CIT0022 doi: 10.1007/978-3-319-40618-3 – volume: 161 start-page: 230 issue: 1 year: 2017 ident: 2021120108545005900_CIT0009 article-title: SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma publication-title: Surgery. doi: 10.1016/j.surg.2016.05.050 – volume: 185 start-page: 1583 issue: 5 year: 2011 ident: 2021120108545005900_CIT0029 article-title: Predictive factors for malignant pheochromocytoma: analysis of 136 patients publication-title: J Urol. doi: 10.1016/j.juro.2010.12.050 – volume: 56 start-page: 513 issue: 8 year: 2019 ident: 2021120108545005900_CIT0002 article-title: Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma publication-title: J Med Genet. doi: 10.1136/jmedgenet-2018-105714 – volume: 102 start-page: 3296 issue: 9 year: 2017 ident: 2021120108545005900_CIT0017 article-title: Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2017-00992 – volume: 12 start-page: e0187398 issue: 11 year: 2017 ident: 2021120108545005900_CIT0015 article-title: Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma publication-title: Plos One. doi: 10.1371/journal.pone.0187398 – volume: 179 start-page: G1 issue: 4 year: 2018 ident: 2021120108545005900_CIT0021 article-title: European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors publication-title: Eur J Endocrinol. doi: 10.1530/EJE-18-0608 – volume: 174 start-page: G1 issue: 5 year: 2016 ident: 2021120108545005900_CIT0027 article-title: European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma publication-title: Eur J Endocrinol. doi: 10.1530/EJE-16-0033 – volume: 14 start-page: 569 issue: 3 year: 2007 ident: 2021120108545005900_CIT0019 article-title: The diagnosis and management of malignant phaeochromocytoma and paraganglioma publication-title: Endocr Relat Cancer. doi: 10.1677/ERC-07-0074 – volume: 48 start-page: 1739 issue: 11 year: 2012 ident: 2021120108545005900_CIT0004 article-title: Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status publication-title: Eur J Cancer Oxf Engl 1990 – volume: 99 start-page: 1915 issue: 6 year: 2014 ident: 2021120108545005900_CIT0023 article-title: Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2014-1498 – volume: 33 start-page: 599 issue: 4 year: 2009 ident: 2021120108545005900_CIT0040 article-title: Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score publication-title: Am J Surg Pathol. doi: 10.1097/PAS.0b013e318190d12e – volume: 13 start-page: 233 issue: 4 year: 2017 ident: 2021120108545005900_CIT0024 article-title: Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2016.185 – volume: 26 start-page: 551 issue: 5 year: 2002 ident: 2021120108545005900_CIT0013 article-title: Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases publication-title: Am J Surg Pathol doi: 10.1097/00000478-200205000-00002 – volume: 51 start-page: 735 issue: 4 year: 2005 ident: 2021120108545005900_CIT0025 article-title: Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines publication-title: Clin Chem. doi: 10.1373/clinchem.2004.045484 – volume: 92 start-page: 3822 issue: 10 year: 2007 ident: 2021120108545005900_CIT0005 article-title: Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2007-0709 – volume: 31 start-page: 181 issue: 2 year: 2017 ident: 2021120108545005900_CIT0038 article-title: Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma publication-title: Cancer Cell. doi: 10.1016/j.ccell.2017.01.001 – volume: 38 start-page: 1443 issue: 8 year: 2020 ident: 2021120108545005900_CIT0001 article-title: Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension publication-title: J Hypertens. doi: 10.1097/HJH.0000000000002438 – volume: 171 start-page: R111 issue: 3 year: 2014 ident: 2021120108545005900_CIT0010 article-title: Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma publication-title: Eur J Endocrinol. doi: 10.1530/EJE-14-0113 – volume: 94 start-page: 2850 issue: 8 year: 2009 ident: 2021120108545005900_CIT0020 article-title: Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2008-2697 – volume: 52 start-page: 241 issue: 4 year: 2011 ident: 2021120108545005900_CIT0030 article-title: Predictive characteristics of malignant pheochromocytoma publication-title: Korean J Urol doi: 10.4111/kju.2011.52.4.241 – volume-title: World Health Organization Classification of Tumours year: 2004 ident: 2021120108545005900_CIT0011 – volume: 6 start-page: 513 issue: 5 year: 2017 ident: 2021120108545005900_CIT0033 article-title: Classification of pulmonary neuroendocrine tumors: new insights publication-title: Transl Lung Cancer Res. doi: 10.21037/tlcr.2017.09.04 – volume: 31 start-page: 1770 issue: 12 year: 2018 ident: 2021120108545005900_CIT0028 article-title: A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal publication-title: Mod Pathol. doi: 10.1038/s41379-018-0110-y – volume: 206 start-page: 305 issue: 5 year: 2010 ident: 2021120108545005900_CIT0034 article-title: Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma publication-title: Pathol Res Pract. doi: 10.1016/j.prp.2010.01.007 – volume: 166 start-page: 901 issue: 5 year: 2019 ident: 2021120108545005900_CIT0026 article-title: Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up publication-title: Surgery. doi: 10.1016/j.surg.2019.04.030 – volume: 14 start-page: 523 year: 2014 ident: 2021120108545005900_CIT0032 article-title: The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study publication-title: BMC Cancer. doi: 10.1186/1471-2407-14-523 – volume: 6 start-page: 6044 year: 2015 ident: 2021120108545005900_CIT0039 article-title: Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas publication-title: Nat Commun. doi: 10.1038/ncomms7044 – volume: 104 start-page: 2367 issue: 6 year: 2019 ident: 2021120108545005900_CIT0016 article-title: Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2018-01968 – volume: 143 start-page: 759 issue: 6 year: 2008 ident: 2021120108545005900_CIT0035 article-title: Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis publication-title: Surgery. doi: 10.1016/j.surg.2008.02.007 – volume: 12 start-page: 1107 issue: 12 year: 1999 ident: 2021120108545005900_CIT0036 article-title: Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas publication-title: Mod Pathol. – volume: 16 start-page: 246 issue: 3 year: 2003 ident: 2021120108545005900_CIT0037 article-title: KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma publication-title: Mod Pathol. doi: 10.1097/01.MP.0000056982.07160.E3 – volume: 22 start-page: 302 issue: 3 year: 2016 ident: 2021120108545005900_CIT0018 article-title: Characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma/paraganglioma: An National Institutes of Health Study publication-title: Endocr Pract. doi: 10.4158/EP15725.OR |
| SSID | ssj0014453 |
| Score | 2.443148 |
| Snippet | Abstract
Context
The behavior of locally advanced pheochromocytoma (LAP) remains unknown.
Objective
We characterized the population with LAP and... Locally advanced pheochromocytoma (LAP) behavior remains unknown. To characterize this population and its recurrence-free survival (RFS). A retrospective... Context: The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective: We characterized the population with LAP and recurrence-free... Context The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective We characterized the population with LAP and recurrence-free... The behavior of locally advanced pheochromocytoma (LAP) remains unknown.CONTEXTThe behavior of locally advanced pheochromocytoma (LAP) remains unknown.We... Abstract Context The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective We characterized the population with LAP and... |
| SourceID | hal proquest gale pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2726 |
| SubjectTerms | Adipose tissue Adipose tissues Catecholamines Gene mutations Human health and pathology Life Sciences Lymph nodes Lymphatic system Medical prognosis Metastases Metastasis Multivariate analysis Neuroendocrine tumors Pheochromocytoma Survival Survival analysis |
| Title | Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33782697 https://www.proquest.com/docview/2956130958 https://www.proquest.com/docview/3170076136 https://www.proquest.com/docview/2507146338 https://amu.hal.science/hal-03662818 |
| Volume | 106 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9swEBdNC2MvY99LmxWtDPZkVkuyZA3GyEZDGG0o3cryZs6y3AQyu0uTQv_73TmyR9jXq6TIyul0-km6-x1jr8skdaoAEzU0ACoVeYTbQhnFhYXY2VILoHvIs4keX6rP02S6wyZtLAy5VbY2sTHURe3ojvytJCI5PHNL_eH6R0RZo-h1tU2hASG1QvG-oRjrsT00ySnq_d7Hk8n5RfeuoFTgpSTHBCOmgcaR4lgoEtHj964gF-GSpd2mgrHuzchXcisO7jc42mxLo4fsQcCTfLhRgEdsx1eP2b2z8GL-hH27oAv1JqQvGi2951_WaBxu6SeBjoTPK35KO9rijg-DRwA_n_nazchVz92t6u_wjo_miBM5gtYlzG9g8ZRdjk6-fhpHIZlC5FSqVxEI5UAZl-TuOBdFGecAJi7RxkBcShSLKQoAcWw8itmTDMrUa2exNPEeUcwztlvVlX_BuHDaSoVlViF6SZwVQEgFoMAJlxD3WdTKLnOBaZwSXiwyOnGgrLONrLMg6z5707W_3nBs_L0lTUVGiw97dBBiCHBcRGOVDXWa6iQ22vbZYKslLhq3VX2Ek9l9jTi2x8PTjMpwS9dEkXWL_-MI5_q_Qxq0qpCF5X-TCducy2yS_rH6ly732auumoZIHm-Vr9fYBQF1paXELp5vNKwbiZSI67Q1-__u_IDdF6TojUfcgO2ulmv_EiHUKj9kPTM1h2F1_AS92Rq3 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviG8KBcwE4imisR0nRppQgVUda6tpbKJvxnEcWqkkox9D_ef427hL3aCKr6e92o7jjzvfnX33O0Ke51FiRWbioIIBEAlLAxALeRBmyoRW5ZIZvIccDGXvTHwYRaMd8mMTC4NulZszsTqos9LiHfkrjkByYHNz-eb8W4BZo_B1dZNCw_jUCtl-BTHmAzuO3Oo7mHDz_cP3sN8vGOsenL7rBT7LQGBFIheBYcIaEdsote2UZXmYGhOHOTCfCXMuIh5nmTGsHTv4vzMpa-eJk1ZBaeScQjAmEAG7AiNcG2T37cHw-KR-xxDC42CiI0TMRh42EuNmMPLRwfy-YJdsSyx64XBljL6ZW3F3v6m_lRjs3iQ3vP5KO2uCu0V2XHGbXB34F_o75NMJXuBXIYRBd-Yc_biEw-gCP_HwJ3RS0D5K0OmKdrwHAj0eu9KO0TXQrhblV_Oadiegl1JQkmdmMjfTu-TsUpb1HmkUZeEeEMqsVFxAmRKgLUVWMYOakTEZEBg3YZMEm7XT1iObY4KNqUYLB9Zar9da-7Vukpd1-_M1psffW-JWaGR26NEaH7MA40LYLN2RSSKjMJaqSVpbLYFJ7Vb1Hmxm_TfE9O51-hrLQIWQCMl1AfPYg73-75BaG1LQ_riZa6YqO1BFyR-rf_FOkzyrq3GI6GFXuHIJXaBhICTn0MX9NYXVI-Ec9Eip4of_7vwpudY7HfR1_3B49IhcZ0j0lTdeizQWs6V7DOrbIn3ieYSSz5fNlj8BTS9ZBw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recurrence-Free+Survival+Analysis+in+Locally+Advanced+Pheochromocytoma%3A+First+Appraisal&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Moog%2C+Sophie&rft.au=Castinetti%2C+Frederic&rft.au=DoCao%2C+Christine&rft.au=Amar%2C+Laurence&rft.date=2021-09-01&rft.pub=Oxford+University+Press&rft.issn=0021-972X&rft.volume=106&rft.issue=9&rft.spage=2726&rft_id=info:doi/10.1210%2Fclinem%2Fdgab202&rft.externalDocID=A688651769 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |